S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ZVSA ZyVersa Therapeutics Inc

5.74

0.00 (0.00%)

Pre Market

Last Updated: 18:21:00

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more ZyVersa Therapeutics Charts.

ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more ZyVersa Therapeutics Charts.

ZyVersa Therapeutics Inc News

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
Monday 29 April 2024 (4 days ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
Thursday 4 April 2024 (4 weeks ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Monday 18 March 2024 (2 months ago) • GlobeNewswire Inc.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
Wednesday 28 February 2024 (2 months ago) • GlobeNewswire Inc.

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Wednesday 14 February 2024 (3 months ago) • GlobeNewswire Inc.

More ZyVersa Therapeutics Inc News Articles

S&P ASX 300 Metals and M...

Australian SE All Ordina...

Verizon Communications

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions